Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 81

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 81
---
 for a period of 180 days immediately
following the commencement of sales of the Initial Public Offering pursuant to Rule 5110(e)(1) of FINRA’s NASD Conduct Rules. Pursuant
to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that
would result in the economic disposition of the securities by any person for a period of 180 days immediately following the commencement
of sales of the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days
immediately following the commencement of sales of the Initial Public Offering except to any underwriter and selected dealer participating
in the Initial Public Offering and their bona fide officers or partners.

Subscription
Receivable — On January 29, 2025, the Company issued a new unsecured subscription promissory note to the Sponsor in
connection with the amended and restated units purchase agreement (as described in Note 5) pursuant to which the Company may borrow
up to an aggregate principal amount of $1,100,000 working capital loans. The Sponsor further agrees that such loans shall be
converted into Private Units, at the price of $10.00 per unit. To the extent the amount of such loans is less than $1,100,000, the
Sponsor acknowledges and agrees that it (or, if applicable, it and any transferees of Private Units) shall surrender for
cancellation any and all rights to up to an aggregate of 110,000 Private Units at $10.00 per unit. As of September 30, 2025, there
was $608,822 outstanding and reported as share subscription receivable on the unaudited balance sheet.

NOTE
8 — FAIR VALUE MEASUREMENTS

The
fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities